Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H, Toyang N, Steele B, Grant J, Ali A, Gordon L, Ngwa W.
Molecules. 2022 Apr 14;27(8):2520. doi: 10.3390/molecules27082520.
Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention.
Fusar-Poli P, Salazar de Pablo G, Correll CU, Meyer-Lindenberg A, Millan MJ, Borgwardt S, Galderisi S, Bechdolf A, Pfennig A, Kessing LV, van Amelsvoort T, Nieman DH, Domschke K, Krebs MO, Koutsouleris N, McGuire P, Do KQ, Arango C.
JAMA Psychiatry. 2020 Jul 1;77(7):755-765. doi: 10.1001/jamapsychiatry.2019.4779.
Risk and protective factors for mental disorders beyond genetics: an evidence-based atlas.
Arango C, Dragioti E, Solmi M, Cortese S, Domschke K, Murray RM, Jones PB, Uher R, Carvalho AF, Reichenberg A, Shin JI, Andreassen OA, Correll CU, Fusar-Poli P.
World Psychiatry. 2021 Oct;20(3):417-436. doi: 10.1002/wps.20894.
Associations of alcohol and tobacco use with psychotic, depressive and developmental disorders revealed via multimodal neuroimaging.
Qiu L, Liang C, Kochunov P, Hutchison KE, Sui J, Jiang R, Zhi D, Vergara VM, Yang X, Zhang D, Fu Z, Bustillo JR, Qi S, Calhoun VD.
Transl Psychiatry. 2024 Aug 7;14(1):326. doi: 10.1038/s41398-024-03035-2.
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
Sass MR, Danielsen AA, Köhler-Forsberg O, Storgaard H, Knop FK, Nielsen MØ, Sjödin AM, Mors O, Correll CU, Ekstrøm C, Vinberg M, Nielsen J, Vilsbøll T, Fink-Jensen A.
BMJ Open. 2023 Jan 31;13(1):e068652. doi: 10.1136/bmjopen-2022-068652.
Mediating Effect of Perceived Stress on the Association between Physical Activity and Sleep Quality among Chinese College Students.
Zhai X, Wu N, Koriyama S, Wang C, Shi M, Huang T, Wang K, Sawada SS, Fan X.
Int J Environ Res Public Health. 2021 Jan 2;18(1):289. doi: 10.3390/ijerph18010289.
Using Mismatch Negativity to Investigate the Pathophysiology of Substance Use Disorders and Comorbid Psychosis.
Ramlakhan JU, Zomorrodi R, Downar J, Blumberger DM, Daskalakis ZJ, George TP, Kiang M, Barr MS.
Clin EEG Neurosci. 2018 Jul;49(4):226-237. doi: 10.1177/1550059418760077. Epub 2018 Mar 4.
Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis.
González-Blanco L, García-Portilla MP, Gutiérrez M, Mezquida G, Cuesta MJ, Urbiola E, Amoretti S, Barcones F, González-Pinto A, Pina-Camacho L, Corripio I, Vieta E, Baeza I, Toll A, Sáiz PA, Bobes J, Bernardo M; PEPs Group.
Schizophr Res. 2021 Oct;236:19-28. doi: 10.1016/j.schres.2021.07.017. Epub 2021 Aug 5.
Use of tobacco in schizophrenia: A double-edged sword.
Fang Y, Wang W, Zhu C, Lin GN, Cheng Y, Zou J, Cui D.
Brain Behav. 2019 Nov;9(11):e01433. doi: 10.1002/brb3.1433. Epub 2019 Oct 11.
Prevalance and course of tobacco use among individuals receiving coordinated specialty care for first-episode psychosis.
Rogers RT, Marino L, Scodes J, Wall M, Nossel I, Dixon L.
Early Interv Psychiatry. 2023 Feb;17(2):192-201. doi: 10.1111/eip.13320. Epub 2022 Jun 24.
